Budget Impact Model for the Use of PCA3 Urine Testing in Prostate Cancer Screening.

Introduction: Continued prostate cancer screening with serum prostate specific antigen in patients with a history of a negative prostate biopsy can result in unnecessary repeat prostate biopsies with significant morbidity and cost. The PCA3 molecular urine test has been shown to be an independent predictor of the diagnosis of significant prostate cancer in men who are still at risk after a negative prostate biopsy. We used a budget impact model to study the potential reduction in unnecessary prostate biopsies and the cost benefits in this population.